Forum Discussion
Two steps forward, one step back – news on access to CDKs in second line treatment
Hello everyone,
BCNA has an update on access to CDKs as
second line treatment. Pfizer have this week advised BCNA about a new capped access
program for the CDK inhibitor palbociclib (lbrance) wh...
This is at least a step in the right direction. Can you please clarify what the restrictions on second line treatment are? I have had chemo, and am currently on a parp inhibitor. Would I be eligible for this access program if the parp inhibitor stops working and I want to try Ibrance? Thank you.